Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Editas Medicine, Inc.NASDAQ: EDIT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.1M fell 29.4% year over year, ahead of the -45.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 1.3% from the prior quarter. Over 3 fiscal years it compounded at -30.1% a year.

Context

  • Stock-based compensation amounted to 24.7% of revenue in FY2025, down 41.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -29.4% holds above the trailing-twelve-month pace of -45.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.1M-1.3% QoQ
Last fiscal yearDec 2025
$10M-53.3% YoY
LTMMar 2026
$9.12M-45.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.4%——
1 year-53.3%——
3-year CAGR-30.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10M USD
Year-over-year change
-53.3%
4-year CAGR
-30.7%

Stock-Based Compensation vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 stock-based compensation of $9.12M is the 8th largest of the 9 companies compared; the peer median is $20.4M.
  • Its year-over-year change of -45.7% is the 8th highest of 9, against a peer median of -14.4%.
  • Stock-based compensation amounts to 23.6% of revenue for EDIT, versus a peer median of 160.2%.
EDIT Competitors Peer median
Stock-Based Compensation for EDIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M +2.8%+19.1%220.8%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M -8.8%-9.5%276.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
PRMEPrime Medicine, Inc.LTM Mar 2026$28.23M +6.4%+65.5%699.8%
BEAMBeam Therapeutics Inc.LTM Jun 2026$12.73M -111.5%+3.8%8.2%
BNTCBenitec Biopharma Inc.LTM Mar 2026$12.56M +183.6%+171.6%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M -45.7%-30.1%23.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M -28.8%-19.0%19.8%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding EDIT) $20.4M-14.4%+4.9%160.2%

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
Deferred Income Tax00000
Stock-Based Compensation43.4M29.29M19.8M21.42M10M
Change in Working Capital(21.41M)8.18M(1.59M)3.45M(31.23M)
Accounts Receivables5.78M(4.88M)(5.04M)(6.08M)1.09M
Inventory(3.35M)0000
Accounts Payables(1.14M)4.37M(1.49M)(2.29M)(2.89M)
Other Working Capital(22.71M)8.69M4.94M11.82M(29.43M)
Other Non-Cash Items1.66M(724K)(3.23M)(3.87M)10.77M
Operating Cash Flow(163.8M)(177.35M)(132.18M)(210.28M)(165.24M)
Capital Expenditures(7.98M)(4.12M)(4.72M)(8.83M)(607K)
Acquisitions (Net)46.49M18K00269K
Purchases of Investments(408.89M)(315.19M)(258.52M)(86.22M)0
Sales of Investments362.4M433.35M259.51M257.19M139.01M
Other Investing Activities(46.49M)0000
Investing Cash Flow(54.47M)114.07M(3.73M)162.15M138.67M
Debt Repayment0000(2.87M)
Common Stock Issued249.46M1.28M117.08M56.03M43.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities32.65M0960K00
Financing Cash Flow282.11M1.28M118.04M56.03M40.47M
Effect of Forex Changes00000
Net Change in Cash63.84M(62M)(17.87M)7.89M13.9M
Free Cash Flow(171.78M)(181.47M)(136.9M)(219.11M)(165.85M)

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.